Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.42 |
| ▸ | F10 | P00742 | 6/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 6/20 | 0.39 |
| ▸ | F9 | P00740 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | RBP4 | P02753 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31438692 | 0.88 | DHODH (0.41) | TRPV1F10IDO1RBP4NPC1 | |
| SCHEMBL589798 | 0.88 | DHODH (0.41) | TRPV1F10IDO1RBP4NPC1 | |
| SCHEMBL2293988 | 0.88 | KLKB1 (0.39) | TRPV1KLKB1IDO1 | |
| SCHEMBL12911867 | 0.86 | TRPV1 (0.45) | TRPV1F10F9RBP4 | |
| SCHEMBL12911593 | 0.84 | TRPV1 (0.44) | TRPV1F10F9RBP4 | |
| SCHEMBL950828 | 0.84 | TRPV1 (0.45) | TRPV1F10KLKB1F9 | |
| SCHEMBL13072905 | 0.83 | TRPV1 (0.43) | TRPV1F10F9RBP4 | |
| SCHEMBL13104923 | 0.83 | IDO1 (0.39) | TRPV1KLKB1IDO1 | |
| SCHEMBL13318531 | 0.82 | F10 (0.46) | TRPV1F10KLKB1F9 | |
| SCHEMBL2958865 | 0.82 | TRPV1 (0.49) | TRPV1F10KLKB1F9RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104496901-B | The manufacture method of anthranilamide compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2016-05-25 | — | — | CN | disclosed |
| EP-2093223-B1 | PROCESS AND INTERMEDIATES FOR PRODUCTION OF AN ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA (JP) | 2013-08-21 | — | — | EP | disclosed |
| US-8115006-B2 | Process for producing anthranilamide compound | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2012-02-14 | — | — | US | disclosed |
| US-20100063293-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA ,LTD. (JP) | 2010-03-11 | — | — | US | disclosed |
| EP-2093223-A1 | PROCESS FOR PRODUCTION OF ANTHRANILAMIDE COMPOUND | ISHIHARA SANGYO KAISHA, LTD. (JP) | 2009-08-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100063293-A1 | PROCESS FOR PRODUCING ANTHRANILAMIDE COMPOUND | NAAA, AAAS, AADAC | TRPV1 3266/4885F10 1441/4885KLKB1 4064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.